SUMMARY:
AAV9-miR871-driven silencing of PMP22 rescues a CMT1A model and provides proof of principle for treating CMT1A using a translatable gene therapy approach.
TITLE:
A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice
DESCRIPTION:
Charcot-Marie-Tooth disease type 1A (CMT1A), the most common inherited demyelinating peripheral neuropathy, is caused by PMP22 gene duplication. Over-expression of wild-type PMP22 in Schwann cells destabilizes the myelin sheath, leading to demyelination and ultimately to secondary axonal loss and disability. No treatments currently exist that modify the disease course. The most direct route to CMT1A therapy will involve reducing PMP22 to normal levels. To accomplish this, we developed a gene…
CONTENT:
J Clin Invest. 2022 May 17:e159814. doi: 10.1172/JCI159814. Online ahead of print.
ABSTRACT
Charcot-Marie-Tooth disease type 1A (CMT1A), the most common inherited demyelinating peripheral neuropathy, is caused by PMP22 gene duplication. Over-expression of wild-type PMP22 in Schwann cells destabilizes the myelin sheath, leading to demyelination and ultimately to secondary axonal loss and disability. No treatments currently exist that modify the disease course. The most direct route to CMT1A therapy will involve reducing PMP22 to normal levels. To accomplish this, we developed a gene therapy strategy to reduce PMP22 using novel artificial microRNAs targeting human and mouse PMP22/Pmp22 mRNAs. Our lead therapeutic microRNA, miR871, was packaged into an AAV9 vector and delivered by lumbar intrathecal injection into C61-het mice, a model of CMT1A. AAV9-miR871 efficiently transduced Schwann cells in C61-het peripheral nerves and reduced human and mouse PMP22/Pmp22 mRNA and protein levels. Treatment at early and late stages of the disease significantly improved multiple functional outcome measures and nerve conduction velocities. Furthermore, myelin pathology in lumbar roots and femoral motor nerves was ameliorated. Treated mice also showed reductions in circulating biomarkers of CMT1A. Taken together, our data demonstrate that AAV9-miR871-driven silencing of PMP22 rescues a CMT1A model and provides proof of principle for treating CMT1A using a translatable gene therapy approach.
PMID:35579942 | DOI:10.1172/JCI159814
SOURCE:
The Journal of clinical investigation
TAGS:
AAV9miR871driven silencing of PMP22
CATEGORY:
Research
SUBCATEGORY:
n/a
DATE – PUBLISHED:
2022-05-17T16:25:13Z
DATE – DOI: 2022-05-17T16:25:13Z
DATE – PUBMED: 2022 May 17
DATE OUTPUT MATCHED: True
DATE – ADDED:
Tue, 17 May 2022 06:00:00 -0400
DATE – RETRIEVED:
05/17/22 05:21PM
2022-05-17T17:21:36-04:00
FEATURED IMAGE:
Media Uploaded (image/png)
IDENTIFIER:
pmid:35579942,doi:10.1172/JCI159814
PUBMED ID:
pubmed:35579942
DOI:
10.1172/JCI159814
LINK – PUBMED:
https://pubmed.ncbi.nlm.nih.gov/35579942/
LINK – DOI:
https://doi.org/10.1172/JCI159814
LINK – PUBLISHER:
http://www.jci.org/articles/view/159814
REFERENCES:
CMT Treatment Report, Urgent Research, 2022-05-17T17:21:36-04:00, https://www.cmttreatmentreport.com.